Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2013 | 12-2012 | 12-2011 | 12-2010 | 12-2009 | |
Sales | 1,211,975 | 1,527,042 | 1,410,626 | 143,370 | 101,889 |
Cost of Goods | 130,277 | 279,885 | 80,505 | 12,730 | 14,202 |
Gross Profit | 1,081,698 | 1,247,157 | 1,330,121 | 130,640 | 87,687 |
Operating Expenses | 1,691,983 | 1,201,315 | 1,216,806 | 827,447 | 701,901 |
Operating Income | -610,008 | 46,727 | 113,820 | -696,077 | -614,012 |
Interest Expense | 22,926 | 15,040 | 37,681 | 19,275 | 13,192 |
Other Income | 6,890 | 309 | -15,694 | -39,274 | -14,974 |
Pre-tax Income | -626,044 | 31,996 | 60,445 | -754,626 | -642,178 |
Income Tax | -122,422 | -275 | 19,266 | N/A | 0 |
Net Income Continuous | -503,622 | 32,271 | 41,179 | -754,626 | -642,178 |
Net Income Discontinuous | -183,928 | -83,406 | N/A | N/A | N/A |
Minority Interests | -242,522 | 55,897 | 11,605 | N/A | 0 |
Net Income | $-445,028 | $-107,032 | $29,574 | $-754,626 | $-642,178 |
EPS Basic Total Ops | -1.98 | -0.50 | 0.14 | -3.77 | -3.71 |
EPS Basic Continuous Ops | -2.24 | 0.15 | 0.20 | -3.77 | -3.71 |
EPS Basic Discontinuous Ops | 0.26 | -0.65 | N/A | N/A | N/A |
EPS Diluted Total Ops | -1.98 | -0.50 | 0.14 | -3.77 | -3.71 |
EPS Diluted Continuous Ops | -2.24 | 0.15 | 0.20 | -3.77 | -3.71 |
EPS Diluted Discontinuous Ops | 0.26 | -0.65 | N/A | N/A | N/A |
EBITDA(a) | $-561,643 | $84,918 | $148,861 | $-665,618 | $-583,905 |